Quadrant HealthCom buys Dowden journals

Share this article:

Quadrant HealthCom purchased the journals division of Dowden Health Media from Lebhar-Friedman. Terms of the deal were not disclosed.

The transaction, brokered by media bankers Desilva + Phillips, closed yesterday. It gives Quadrant HealthCom four Dowden Professional Publications journals – OBG Management, Current Psychiatry, The Journal of Family Practice and Mayo Clinic Proceedings – along with Dowden's events division. About 30 Dowden employees will relocate to Quadrant's headquarters in Parsippany, NJ.

Quadrant president Stephen Stoneburn said in a statement: “We are excited about the opportunity to add leading properties in new therapeutic and audience markets and to expand our already strong presence in the women's healthcare sector.”

Quadrant's stable of nine journals includes The Female Patient.

Lebhar-Friedman acquired Dowden in 2005, and is keeping Dowden's hospital marketing group and medical education business.

Lebhar-Friedman president Roger Friedman said that with the dropoff in journal ad pages and numerous blockbusters losing patent protection in the next few years, his company was looking for less exposure to advertising-dependent businesses. "We wanted to get away from products that were strictly advertising-based, and the professional journals group at Dowden was almost entirely advertising-based," said Friedman. "We'd rather be in databases, research, education -- more proprietary products."


Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in News

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...